Table 2.
PGE-M by Smoking Status and NSAID Use
| Median (Range)† | Median (Range)† | P value | |
|---|---|---|---|
| Smoking Status | Never smokers | Ever smokers | |
| Lung Metastases (group 1A) n=99 | 6.1 (0.7–43.4) n=56 | 7.4 (0.8–28.9) n=43 | 0.54 |
| No Known Lung Metastases (group 1B) n=100 | 4.8 (0.7–26.8) n=52 | 4.6 (1.3–26.7) n=48 | 0.96 |
| Controls (group 2) n=200 | 4.0 (0.9–62.6) n=96 | 4·5 (1.0–26.8) n=104 | 0.45 |
| Overall NSAID Use | ≤7 days since NSAID | > 7days since NSAID | |
| Lung Metastases (group 1A) n=99 | 5.4 (0.7–19.3) n=49 | 7.4 (1.8–43.4) n=50 | 0.005 |
| No Known Lung Metastases (group 1B) n=100 | 5.2 (0.7–26.7) n=47 | 4.1 (1.3–26.8) n=53 | 0.22 |
| Controls (group 2) n=200 | 3.8 (1.0–62.6) n=95 | 4.5 (0.9–30.8) n=105 | 0.04 |
| Interaction Between Smoking, NSAIDs and PGE-M | |||
| Ever smokers | ≤7 days since NSAID | > 7days since NSAID | |
| Lung Metastases (group 1A) n=99 | 5.2 (0.8–19.3) n=25 | 10.6 (2.9–28.9) n=18 | 0.01 |
| No Known Lung Metastases (group 1B) n=100 | 5.5 (1.3–26.7) n=21 | 3.6 (1.4–12.5) n=27 | 0.08 |
| Controls (group 2) n=200 | 3.8 (1.0–26.8) n=51 | 5.2 (1.5–24.2) n=53 | 0.03 |
| Never smokers | ≤7 days since NSAID | > 7days since NSAID | |
| Lung Metastases (group 1A) n=99 | 5.6 (0.7–19.1) n=24 | 6.7 (1.8–43.4) n=32 | 0.13 |
| No Known Lung Metastases (group 1B) n=100 | 4.9 (0.7–19.6) n=26 | 4.6 (1.3–26.8) n=26 | 0.83 |
| Controls (group 2) n=200 | 3.8 (1.2–62.6) n=44 | 4.0 (0.9–30.8) n=52 | 0.43 |
†
normalized to urinary creatinine and expressed as ng/mg creatinine